ALEC Alector Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ALEC

Price (delayed)

$6.49

Market cap

$625.54M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.38

Enterprise value

$588.99M

Alector is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. The Company is developing a broad portfolio of innate immune system ...

Highlights
ALEC's EPS is up by 15% YoY and by 12% from the previous quarter
The debt has contracted by 11% YoY and by 3.5% from the previous quarter
The quick ratio has contracted by 50% YoY but it has grown by 11% from the previous quarter
The equity has increased by 33% QoQ but it has decreased by 2.2% YoY
ALEC's gross profit is down by 23% YoY
The revenue has declined by 23% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://alector.com
Peers: OMGA ONCT

Key stats

What are the main financial stats of ALEC
Market
Shares outstanding
96.38M
Market cap
$625.54M
Enterprise value
$588.99M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.47
Price to sales (P/S)
6.32
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.11
Earnings
Revenue
$96.41M
EBIT
-$116.3M
EBITDA
-$107.26M
Free cash flow
-$198.85M
Per share
EPS
-$1.38
Free cash flow per share
-$2.12
Book value per share
$1.87
Revenue per share
$1.03
TBVPS
$6.77
Balance sheet
Total assets
$635.49M
Total liabilities
$456.59M
Debt
$37.56M
Equity
$178.91M
Working capital
$416.47M
Liquidity
Debt to equity
0.21
Current ratio
3.53
Quick ratio
3.42
Net debt/EBITDA
0.34
Margins
EBITDA margin
-111.3%
Gross margin
100%
Net margin
-125.1%
Operating margin
-150.8%
Efficiency
Return on assets
-18.3%
Return on equity
-71.8%
Return on invested capital
-26.2%
Return on capital employed
-24.7%
Return on sales
-120.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ALEC stock price

How has the Alector stock price performed over time
Intraday
0%
1 week
11.32%
1 month
50.23%
1 year
3.67%
YTD
-18.67%
QTD
42.95%

Financial performance

How have Alector's revenue and profit performed over time
Revenue
$96.41M
Gross profit
$96.41M
Operating income
-$145.33M
Net income
-$120.61M
Gross margin
100%
Net margin
-125.1%
ALEC's operating margin is down by 32% year-on-year but it is up by 3.5% since the previous quarter
ALEC's gross profit is down by 23% YoY
The revenue has declined by 23% year-on-year
The net margin has contracted by 17% YoY but it has grown by 7% from the previous quarter

Growth

What is Alector's growth rate over time

Valuation

What is Alector stock price valuation
P/E
N/A
P/B
3.47
P/S
6.32
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.11
ALEC's EPS is up by 15% YoY and by 12% from the previous quarter
The equity has increased by 33% QoQ but it has decreased by 2.2% YoY
ALEC's P/B is 23% below its 5-year quarterly average of 4.5
The stock's price to sales (P/S) is 80% less than its 5-year quarterly average of 31.2 but 9% more than its last 4 quarters average of 5.8
The revenue has declined by 23% year-on-year

Efficiency

How efficient is Alector business performance
The return on equity has declined by 25% year-on-year but it has increased by 7% since the previous quarter
ALEC's ROS is down by 16% YoY but it is up by 7% from the previous quarter
Alector's ROA has decreased by 11% YoY but it has increased by 3.7% from the previous quarter
The return on invested capital has declined by 11% year-on-year but it has grown by 3.7% since the previous quarter

Dividends

What is ALEC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALEC.

Financial health

How did Alector financials performed over time
ALEC's total assets is 39% greater than its total liabilities
The quick ratio has contracted by 50% YoY but it has grown by 11% from the previous quarter
Alector's current ratio has decreased by 49% YoY but it has increased by 11% from the previous quarter
The debt is 79% less than the equity
The equity has increased by 33% QoQ but it has decreased by 2.2% YoY
The debt to equity is down by 28% since the previous quarter and by 9% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.